Retatrutide: The Breakthrough Triple Agonist Redefining Weight Loss in 2025
In 2025, a new name is reshaping the landscape of medical weight loss: Retatrutide. This cutting-edge triple agonist has become one of the most anticipated therapies in obesity and metabolic health, showing unprecedented results in clinical trials. Developed by Eli Lilly, the pharmaceutical innovator behind Mounjaro (tirzepatide), Retatrutide combines three powerful mechanisms to accelerate fat…
